Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Shade

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Radiology|February 15, 2017
Clinical Safety of Bariatric Arterial Embolization: Preliminary Results of the BEAT Obesity TrialClifford R Weiss, Olaguoke Akinwande, Kaylan Paudel, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 8, 2019
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trialStephan Ehrhardt, Anton P Porsteinsson, Cynthia A Munro, et al.
Neurology|July 1, 2018
Effects of deep brain stimulation on rest tremor progression in early stage Parkinson diseaseMallory L Hacker, Mahlon R DeLong, Maxim Turchan, et al.
BMJ Open|September 24, 2018
Development of the individualised Comparative Effectiveness of Models Optimizing Patient Safety and Resident Education (iCOMPARE) trial: a protocol summary of a national cluster-randomised trial of resident duty hour policies in internal medicineJudy A Shea, Jeffrey H Silber, Sanjay V Desai, et al.
The New England Journal of Medicine|March 12, 2019
Patient Safety Outcomes under Flexible and Standard Resident Duty-Hour RulesJeffrey H Silber, Lisa M Bellini, Judy A Shea, et al.
JAMA|February 20, 2014
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trialAnton P Porsteinsson, Lea T Drye, Bruce G Pollock, et al.
The American Journal of Psychiatry|April 2, 2016
Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD StudyAnne K Leonpacher, Matthew E Peters, Lea T Drye, et al.
Plos One|June 11, 2014
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trialLea T Drye, David Spragg, D P Devanand, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 5, 2015
Time to Response to Citalopram Treatment for Agitation in Alzheimer DiseaseDaniel Weintraub, Lea T Drye, Anton P Porsteinsson, et al.
International Psychogeriatrics|August 26, 2015
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trialPaul B Rosenberg, Lea T Drye, Anton P Porsteinsson, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Radiology|February 15, 2017
Clinical Safety of Bariatric Arterial Embolization: Preliminary Results of the BEAT Obesity TrialClifford R Weiss, Olaguoke Akinwande, Kaylan Paudel, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 8, 2019
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trialStephan Ehrhardt, Anton P Porsteinsson, Cynthia A Munro, et al.
Neurology|July 1, 2018
Effects of deep brain stimulation on rest tremor progression in early stage Parkinson diseaseMallory L Hacker, Mahlon R DeLong, Maxim Turchan, et al.
BMJ Open|September 24, 2018
Development of the individualised Comparative Effectiveness of Models Optimizing Patient Safety and Resident Education (iCOMPARE) trial: a protocol summary of a national cluster-randomised trial of resident duty hour policies in internal medicineJudy A Shea, Jeffrey H Silber, Sanjay V Desai, et al.
The New England Journal of Medicine|March 12, 2019
Patient Safety Outcomes under Flexible and Standard Resident Duty-Hour RulesJeffrey H Silber, Lisa M Bellini, Judy A Shea, et al.
JAMA|February 20, 2014
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trialAnton P Porsteinsson, Lea T Drye, Bruce G Pollock, et al.
The American Journal of Psychiatry|April 2, 2016
Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD StudyAnne K Leonpacher, Matthew E Peters, Lea T Drye, et al.
Plos One|June 11, 2014
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trialLea T Drye, David Spragg, D P Devanand, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 5, 2015
Time to Response to Citalopram Treatment for Agitation in Alzheimer DiseaseDaniel Weintraub, Lea T Drye, Anton P Porsteinsson, et al.
International Psychogeriatrics|August 26, 2015
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trialPaul B Rosenberg, Lea T Drye, Anton P Porsteinsson, et al.
Pageof 8